Codexis is a company.
Codexis has raised $37.0M across 1 funding round.
Key people at Codexis.
Codexis has raised $37.0M in total across 1 funding round.
Key people at Codexis.
Codexis, Inc. (NASDAQ: CDXS) is a biotechnology company specializing in protein engineering, developing high-performance enzymes via its proprietary CodeEvolver® platform to enable scalable, sustainable manufacturing solutions primarily for therapeutics.[1][2][3] It serves pharmaceutical, biopharmaceutical, food, and industrial biotech sectors by creating custom enzymes that improve drug manufacturing efficiency, reduce waste, and support RNAi therapeutics, diagnostics, and small molecule synthesis—solving challenges like high costs, impurities, and environmental impact in traditional chemical processes.[1][2][4] With a focus on greener chemistry and faster timelines, Codexis powers approved drugs and partnerships, deriving most revenue from the Americas while operating in healthcare/biotechnology (NAICS 541714).[2][3]
The company's growth momentum stems from expanding platforms like ECO Synthesis™ for RNAi manufacturing and collaborations with firms like Takeda and Merck, alongside enzymes in marketed products like Lipitor and Januvia building blocks.[3][4][6] As a small-value stock in biotech, it emphasizes innovation for global health and sustainability.[3][5]
Codexis was incorporated in 2002 in Redwood City, California, building on directed evolution technology and going public on NASDAQ in April 2010.[6] A pivotal early moment came in October 2010 when it acquired Maxygen's MolecularBreeding technology portfolio, bolstering its enzyme engineering capabilities.[6] The company emerged from advancements in protein engineering, earning U.S. EPA Presidential Green Chemistry Challenge Awards in 2006 for Lipitor work and 2010 for Merck's Januvia ingredient, highlighting its rapid traction in sustainable pharma manufacturing.[6]
Key milestones include 2017's development of a phenylalanine ammonia-lyase (PAL) enzyme for phenylketonuria (in-licensed by Nestle), 2020 partnerships with Takeda for gene therapies and Molecular Assemblies for DNA synthesis enzymes, and ongoing evolution toward RNAi and diagnostics.[6] Leadership, including CEO Alison Moore (PhD), CFO Georgia Erbez, and CSO Stefan Lutz (PhD), drives this from biopharma and manufacturing expertise.[7]
Codexis stands out through enzyme engineering that outperforms legacy methods in speed, sustainability, and precision:
Codexis rides the sustainable biotech wave, capitalizing on rising demand for enzymatic manufacturing amid RNAi therapeutics growth (e.g., siRNA for diseases) and ESG pressures in pharma.[2][4][5] Timing aligns with post-2020 shifts toward greener API synthesis and precision medicine, where traditional methods falter on scalability and waste—Codexis' platforms address this, powering nucleic acid synthesis and diagnostics amid genomic booms.[3][6]
Market forces like regulatory pushes for sustainability (e.g., EPA awards) and RNAi market expansion favor it, influencing the ecosystem by enabling partners to hit faster approvals and lower costs—e.g., enzymes in blockbuster drugs set standards for biocatalysis adoption.[1][6] In biotech's $1T+ landscape, it bridges R&D (NAICS 541714) to commercialization, amplifying impact for human health and environment.[2][5]
Codexis is poised to expand its enzyme platforms into next-gen RNAi scaling and gene therapies, leveraging CodeEvolver® and ECO Synthesis™ for more partnerships amid biotech's sustainability pivot.[2][3][4] Trends like AI-enhanced protein design and ESG mandates will accelerate adoption, potentially boosting revenue through diagnostics and food enzymes while navigating small-value stock volatility.[3][5][6]
Its influence may evolve as the go-to platform for "unsolvable" manufacturing, compounding from drug approvals to broader biosolutions—transforming biology as the ultimate technology, as its mission states.[1] This positions Codexis to redefine therapeutic possibilities, building on decades of firsts.
Codexis has raised $37.0M in total across 1 funding round.
Codexis's investors include M34 Capital.
Codexis has raised $37.0M across 1 funding round. Most recently, it raised $37.0M Series D in August 2006.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2006 | $37.0M Series D | M34 Capital |